Paper Picks
Take a look at our favourite publications around biotransformation and metabolism of drugs in Hypha’s “Paper Picks”.
Hypha's Paper Picks
This discussion paper provides an industry perspective on UGT DDIs and recent updates on the utility of in vitro studies to investigate them.
We’re kicking off 2026 with a paper pick that beautifully highlights the role that hydroxyls and water networks can play in dramatically improving binding affinities.
Nina Isoherranen discusses the often underestimated role of metabolites in causing drug-drug interactions.
In this paper, AstraZeneca scientists discuss integration of ADME studies and PK modeling data to achieve an acceptable PK profile for camizestrant (AZD9833) in humans.
In this interesting paper, Gilead scientists highlight the potential importance of intestinal excretion of drugs with low metabolic clearance.
We look at the metabolism of iptacopan and the biocatalytic paths used for synthesis of selected metabolites as analytical reference standards.
An interesting paper on oxidative biotransformation of elinzanetant by CYP3A4 to 3 active metabolites is the subject of our paper pick for February 2025.
In this paper an IQ Consortium industry working group provide interesting insights into in vitro MetID practices and their effectiveness in predicting circulating human metabolites.
Major biotransformation routes of aficamten involving hydroxylation, onwards glucuronidation and gut metabolism are highlighted and discussed in this article.
There are several interesting facets to this paper in which the ADME characteristics and major circulating glucuronides of icenticaftor are discussed.
Two recent papers exploring the role of NMR spectroscopy in drug discovery and development have prompted us to highlight the role of NMR in drug metabolism in our blog this month.
The discovery of novel human metabolites of inavolisib derived from the heme breakdown product stercobilin is the topic of our paper pick this month.
Stay up to date with the latest news from Hypha Discovery
Sign up for our quarterly newsletters and monthly "Metabolite Tales" blog
Ready to begin? Our scientists are available to talk through your requirements
Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.